Qiang Zhao
Director/Miembro de la Junta en Shanghai Haihe Biopharma Co., Ltd. .
Cargos activos de Qiang Zhao
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Shanghai Haihe Biopharma Co., Ltd.
 Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | Director/Miembro de la Junta | 08/09/2020 | - |
| Independent Dir/Board Member | 08/09/2020 | - |
Historial de carrera de Qiang Zhao
Antiguos cargos conocidos de Qiang Zhao.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD. | Director/Miembro de la Junta | 26/05/2017 | 10/06/2023 |
| Independent Dir/Board Member | 26/05/2017 | 10/06/2023 | |
| JOINTO ENERGY INVESTMENT CO., LTD. HEBEI | Director/Miembro de la Junta | 12/09/2014 | - |
| Independent Dir/Board Member | 12/09/2014 | - |
Estadísticas
Internacional
| China | 4 |
Operativa
| Director/Board Member | 3 |
| Independent Dir/Board Member | 3 |
Sectorial
| Utilities | 2 |
| Producer Manufacturing | 2 |
| Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| JOINTO ENERGY INVESTMENT CO., LTD. HEBEI | Utilities |
| BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD. | Producer Manufacturing |
| Empresas privadas | 1 |
|---|---|
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | Commercial Services |
- Bolsa de valores
- Insiders
- Qiang Zhao
- Experiencia